News, Scientific publications and Events

Congresses: Noventure participates at the second edition of IBS Days

Noventure, as part of its ongoing activities in support of the launch of Gelsectan®, participated with a stand at the IBS Days 2018 in Bologne, Italy, May 17 - 19, 2018. This meeting is intended to provide current views and a look to the future on the rapidly advancing field of IBS. One of the lectures was devoted to mucosal barrier and permeability, which is a hot topic among gastroenterologists specialized in IBS management. Gelsectan® contains mucoprotectors which improve the resistance of the mucosal barrier and help restore its normal function. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Allergology / ent News RHINOSECTAN®

News on NOVENTURE participation in 2018 EAACI in Munich

Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI - European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce its presence in the allergy field thanks to its medical device RHINOSECTAN® intended to control and prevent symptoms of rhinitis and rhinosinusitis, especially those of allergic origin. EAACI is the Europe’s largest medical association in the field of allergy and clinical immunology and it offers a unique chance to learn about latest discovery as it gathers KOLs from around the world.

Gastroenterology News TASECTAN® TASECTAN® DUO XILAPLUS®

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.